What is Aplagon Oy?
Aplagon Oy operates at the forefront of pharmaceutical innovation, specializing in the development of locally acting antithrombotic products (APACs). These proprietary solutions are engineered to mitigate the risks associated with vascular interventions, specifically targeting the prevention and management of blood vessel occlusions. By leveraging a sophisticated network of top-tier scientists and laboratories, the company maintains a competitive edge in the life science sector, bridging the gap between complex vascular pathology and effective clinical intervention. Their strategic focus remains on high-impact therapeutic development, ensuring that their medical technology meets the stringent requirements of modern vascular medicine.
How much funding has Aplagon Oy raised?
Aplagon Oy has raised a total of $12.6M across 2 funding rounds:
Other Financing Round
$7.1M
Other Financing Round
$5.5M
Other Financing Round (2025): $7.1M with participation from Fåhraeus Startup & Growth and European Innovation Council and SMEs Executive Agency (EISMEA
Other Financing Round (2026): $5.5M led by Innovestor, Fhraeus Startup and Growth, The European Innovation Council, and Jenny and Antti Wihuri Foundation
Key Investors in Aplagon Oy
Innovestor
Innovestor is a Finnish investment manager specializing in venture capital and life science startups, providing strategic support to foster economic prosperity and innovation.
Fåhraeus Startup & Growth
A venture capital firm based in Sweden that focuses on early-stage and commercial-stage startups at the intersection of life science and deep technology.
Jenny and Antti Wihuri Foundation
An independent Finnish foundation that supports scientific research and social activities, playing a pivotal role in backing long-term academic and medical advancements.
What's next for Aplagon Oy?
With the successful closure of this major strategic investment, Aplagon Oy is poised to transition into a more intensive phase of clinical validation and product maturation. The influx of capital will likely be directed toward scaling research operations and navigating the regulatory pathways necessary for bringing their antithrombotic candidates to market. As the company continues to refine its therapeutic platform, the focus will shift toward expanding its collaborative footprint and solidifying its position as a leader in vascular medicine. Investors remain optimistic that the company's unique approach to localized treatment will provide a significant advantage in the competitive landscape of cardiovascular therapeutics, ultimately driving long-term value for stakeholders and patients alike.
See full Aplagon Oy company page
